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OBJECTIVES We sought to assess the cost implications of two investigation strategies in patients with
unexplained syncope.
BACKGROUND Establishing a diagnosis in patients with unexplained syncope is complicated by infrequent
and unpredictable events. The cost-effectiveness of immediate, prolonged monitoring as an
alternative to conventional diagnostic strategies has not been studied.
METHODS Sixty patients (age 66  14 years; 33 males) with unexplained syncope and LV ejection
fraction 35% were randomized to conventional testing with an external loop recorder, tilt
and electrophysiologic (EP) testing, or prolonged monitoring with an implantable loop
recorder with one-year monitoring. If patients remained undiagnosed after their assigned
strategy, they were offered a crossover to the alternate strategy. Cost analysis of the two testing
strategies was performed.
RESULTS Fourteen of 30 patients who were being monitored were diagnosed at a cost of $2,731 $285
per patient and $5,852 $610 per diagnosis. In contrast, only six of 30 conventional patients
were diagnosed (20% vs. 47%, p  0.029), at a cost of $1,683  $505 per patient (p 
0.0001) and $8,414  $2,527 per diagnosis (p  0.0001). After crossover, a diagnosis was
obtained in 1 of 5 patients undergoing conventional testing, compared with 8 of 21 patients
who completed monitoring (20% vs. 38%, p  0.44). Overall, a strategy of monitoring
followed by tilt and EP testing was associated with a diagnostic yield of 50%, at a cost of
$2,937 $579 per patient and $5,875 $1,159 per diagnosis. Conventional testing followed
by monitoring was associated with a diagnostic yield of 47%, at a greater cost of $3,683 
$1,490 per patient (p 0.013) and a greater cost per diagnosis ($7,891 $3,193, p 0.002).
CONCLUSIONS A strategy of primary monitoring is more cost-effective than conventional testing in
establishing a diagnosis in recurrent unexplained syncope. (J Am Coll Cardiol 2003;42:
495–501) © 2003 by the American College of Cardiology Foundation
The current approach to the investigation of patients with
unexplained syncope involves short-term electrocardio-
graphic monitoring or provocative testing with head-up tilt
and electrophysiologic (EP) testing (1–5). Recent advances
in long-term monitoring with an implantable loop recorder
See page 502
have provided an opportunity to obtain a correlation be-
tween symptom and rhythm in the majority of patients
(6–13). This new technology is associated with a higher
diagnostic yield than conventional testing but requires a
minor invasive procedure and is associated with a significant
initial cost. In addition, a strategy of prolonged monitoring
may defer a diagnosis because it is dependent on the
recurrence of symptoms potentially associated with morbid-
ity and rarely mortality.
We performed a prospective, randomized trial of pro-
longed monitoring versus conventional testing in 60 pa-
tients undergoing cardiac testing for unexplained syncope
(13). The current study reflects the cost analysis of the two
diagnostic strategies.
METHODS
Patients. Patients referred to the Arrhythmia Service at
London Health Sciences Center for investigation of syn-
cope were approached to participate in a prospective, ran-
domized trial comparing two diagnostic approaches to
syncope. The details of this trial have been reported previ-
ously (13). In summary, 60 patients with recurrent unex-
plained syncope or a single episode of syncope associated
with injury that warranted cardiovascular investigation were
enrolled in a prospective, randomized trial comparing con-
ventional testing to prolonged monitoring with an implant-
able loop recorder (Table 1). Before enrollment, patients
underwent a clinical assessment, including postural blood
pressure testing, a minimum of 24 h of baseline ambulatory
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monitoring or in-patient telemetry, and a transthoracic
echocardiogram. Additional neurologic or cardiovascular
testing before enrollment performed by the referring phy-
sician was recorded but not mandated by the protocol.
Patients were excluded if their left ventricular (LV) ejection
fraction was 35%, if they were unlikely to survive for one
year, or if they were unable to provide follow-up or give
informed consent. Patients with a presentation typical of
neurally mediated syncope at the baseline assessment were
considered to have this diagnosis and were excluded.
Patients were randomized to a conventional investigation
strategy, including a two- to four-week period of monitor-
ing with an external loop recorder, followed by tilt-table and
EP testing (14,15). Patients randomized to a strategy of
prolonged monitoring underwent implantation of a Reveal
implantable loop recorder (Medtronic, Minneapolis, Min-
nesota). The details of the implantable loop recorder have
been reported (10,16–18). Monitored patients underwent
follow-up for one year. For the purpose of analysis in the
monitoring strategy, a diagnosis was defined as obtaining a
correlation between symptom and rhythm in patients during
spontaneous syncope or presyncope that resembled the
symptoms experienced before enrollment. In the conven-
tional arm, a diagnosis was defined according to standard
published criteria for tilt and EP testing (5,14,19–23).
Crossover. If the assigned strategy did not provide a
diagnosis, patients were offered a crossover to the alternate
strategy. An implantable loop recorder was offered to all
conventional patients immediately after tilt and EP testing
was negative. Tilt and EP testing were offered to monitored
patients if a diagnosis was not obtained after one year of
follow-up. All patients provided written, informed consent.
The protocol was approved by the University of Western
Ontario’s Institutional Review Board.
Follow-up. Patients were seen one week after loop recorder
implantation for wound assessment and to reinforce patient
understanding of the activation process. Subsequent
follow-up occurred at 1, 2, 3, 6, 9, and 12 months. Patients
were seen immediately after a symptomatic event. Patients
undergoing conventional testing were seen at enrollment
and in conjunction with prescribed testing. If undiagnosed
patients refused crossover, they were asked to contact the
study nurse in the event of recurrence.
Cost determination. Before being enrolled in the study, all
patients were interviewed and medical records were re-
viewed to determine previous health care resource utiliza-
tion with respect to the investigation of syncope. After
enrollment, resource use was charted according to patient
outcome in the study protocol. The costs of investigations
were calculated based on the Ontario Health Insurance
Program fee schedule for technical and professional fees and
also included an estimate of materials, labor, maintenance,
and overhead for hospital-based investigations (Table 1).
Abbreviations and Acronyms
AV  atrioventricular
EP  electrophysiologic
ICER  incremental cost-effectiveness ratio
LV  left ventricular
Table 1. Cost Calculations for Testing
Test Materials Technical/Labor Services Overhead Professional Total
External loop recording 2.75 150.00 6.00 46.80 129.80 335.35
Transtelephonic monitoring 2.75 29.40 0 8.82 56.80 97.77
Holter monitoring 5.00 57.45 0 17.24 45.60 125.29
Echocardiography 3.00 120.40 6.00 37.92 105.70 273.02
Tilt-table test 16.00 31.00 6.00 11.10 106.55 170.65
EP testing 325.00 125.00 28.00 45.90 853.60 1,377.50
Implanted loop recorder 2,237.00 50.00 3.00 15.90 139.40 2,445.30
Implanted loop recorder removal 3.00 50.00 3.00 15.90 139.40 211.30
Cardiac catheterization 109.92 50.00 6.00 16.80 399.20 581.92
Stress test 51.52 33.30 3.00 10.89 56.40 155.11
Stress MIBI 339.71 66.60 6.00 21.78 314.30 748.39
Radionuclide wall motion study 0 137.25 0 41.18 75.10 253.53
Electrocardiography 3.00 30.52 3.00 10.06 9.25 55.83
Electroencephalography 0 24.75 0 7.43 49.25 81.43
Loop recorder follow-up 0 8.90 0 2.67 9.05 20.62
Neurology consult 0 0 0 0 109.05 109.05
Cardiology consult 0 0 0 0 109.05 109.05
Family practice assessment 0 0 0 0 53.13 53.13
Family practice follow-up 0 0 0 0 29.05 29.05
Emergency room visit 0 31.53 0 9.46 26.55 67.54
One day in-hospital monitoring 50.00 145.54 20.00 49.66 17.70 282.90
Head CT* 400.00
Head MRI* 750.00
Carotid Doppler* 250.00
*Costs (2002 Canadian dollars) were estimated based on peer-reviewed research billing codes.
CT  computed tomography; EP  electrophysiologic; MIBI  methoxyisobutyl isonitrile; MRI  magnetic resonance imaging.
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For example, the Holter monitoring cost was calculated by
adding the material cost of $5.00, technical and labor fees of
$57.45, hospital overhead of $17.24, and a professional fee
of $45.90, for a total of $125.29 ($80.10 U.S. dollars; 82.09
Euros, converted October 20, 2002). No service charge was
included for the Holter cost calculation, because the current
service contract is included in the hospital overhead calcu-
lation. For neurologic testing, material and maintenance
data were unavailable. To approximate the cost of neuro-
logic testing, peer-reviewed research billing rates were used
to calculate cost. Overall costs and cost per diagnosis were
estimated based on the primary diagnostic strategy, cross-
over, and combined strategies. All costs were considered
direct medical costs that were assessed from a societal
perspective and expressed in 2002 Canadian dollars. The
incremental cost-effectiveness ratio (ICER) was calculated
as the difference between the total cost of the monitoring
strategy and the conventional strategy divided by the differ-
ence in diagnostic efficacy between the monitoring strategy
and conventional strategy. All measures were calculated per
person.
Analysis. Continuous variables were compared by the Stu-
dent t test. Categorical variables were compared by the
chi-square test. A p value 0.05 was considered statistically
significant.
RESULTS
Sixty patients with unexplained syncope were randomized in
the study. There was no difference in baseline variables
between the groups (Table 2). Structural heart disease was
present in 23 patients (38%). Left ventricular function was
well preserved in most patients, with an ejection fraction
50% in only six patients. Before enrollment, neurologic
testing was performed in 36 patients (60%), with brain
imaging in 25 (42%) and an electroencephalogram in 19
(32%). The cost of neurologic testing was $475  $295 per
patient in the 36 patients who were tested and $285 $326
for all 60 patients (Table 3). The overall cost of testing
before enrollment was $1,327  $503 (median $1,241),
with a range of $507 to $2,466.
Primary strategy. In the 30 patients randomized to a
strategy of monitoring, a diagnosis was obtained in 14 (Fig.
1). This included bradycardia in 10 patients, supraventric-
ular tachycardia in one patient, and oscillation of sinus rates
in keeping with neurocardiogenic syncope in the remaining
three patients. In 16 patients, symptoms did not recur
during the 12-month follow-up period. One patient failed
to appropriately activate the loop recorder after an episode
of syncope, and no further episodes occurred after the
failure. The cost of a primary strategy of monitoring was
$2,731  $285, and the cost per diagnosis was $5,852 
$610 (Table 3). In the 30 patients in the conventional arm,
a diagnosis was obtained in only six patients (20% vs. 47%
by monitoring, p  0.029). One patient had symptomatic
third-degree atrioventricular (AV) block while wearing an
external loop recorder; two patients had a positive tilt test;
and EP testing demonstrated poor AV node function in two
patients and inducible ventricular tachycardia in one patient.
The cost of the investigation with the conventional strategy
was significantly less than investigation with the primary
strategy of monitoring ($1,683  $505, p  0.0001), but
the cost per diagnosis was significantly greater ($8,414 
$2,527, p  0.0001). The ICER for an immediate strategy
of monitoring was $3,930.
Table 2. Clinical Characteristics of Conventional and
Monitored Groups
Conventional
(n  30)
Monitored
(n  30)
Age (yrs) 64  14 68  14
Male gender 14 (47%) 19 (63%)
Baseline ECG normal 22 (73%) 20 (67%)
Structural heart disease 10 (33%) 13 (43%)
LVEF (%) 55  6 55  8
Number of syncopal episodes 5.8  6.6 4.1  3.3
Duration of syncope (yrs) 8.7  26.6 6.6  12.1
Data are presented as the mean value  SD or number (%) of patients.
ECG  electrocardiogram; LVEF  left ventricular ejection fraction.
Table 3. Cost of Testing Before and During the Study
Cost Variable Monitoring Conventional p Value ICER
Before enrollment (n) 30 30
Neurologic $275  $357 $294  $299 0.83
Cardiovascular $606  $155 $578  $134 0.46
Total $1,363  $507 $1,290  $504 0.57
Primary strategy (n) 30 30 $3,930
Cost $2,731  $285 $1,683  $505  0.0001
Cost/diagnosis $5,852  $610 $8,414  $2,527  0.0001
Crossover strategy (n) 5 21 $6,127
Cost* $2,657 $1,548
Cost/diagnosis* $6,974 $7,741
Overall (n) 30 30
Cost $2,937  $579 $3,683  $1,490 0.013 $22,380
Cost/diagnosis $5,875  $1,159 $7,891  $3,193 0.002
*Standard deviations are not reported, because all patients in each group underwent identical testing, with identical costs.
ICER  incremental cost-effectiveness ratio.
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Crossover. Five of the 16 patients who remained undiag-
nosed after one year of monitoring consented to a crossover
to conventional testing. Because of the previous monitoring,
patients did not undergo short-term monitoring with an
external loop recorder. Tilt testing was negative in all five
patients. Electrophysiologic testing induced sustained AV
node reentrant tachycardia associated with hypotension in
one patient. This patient underwent slow pathway ablation.
Twenty-one of 24 patients with negative conventional
testing underwent implantation of a loop recorder. A
diagnosis was obtained in eight patients, and symptoms did
not recur in the remaining 13 patients during 12 months of
follow-up. In the eight patients who were diagnosed,
bradycardia was noted in four and tachycardia in two. Two
patients had sinus rhythm recorded during syncope, with
phasic motion artifact on the recorded signal suggestive of
seizure activity (24). Neurologic consultation led to anticon-
vulsant therapy, with resolution of symptoms. The cost and
cost per diagnosis in the crossover patients is shown in
Table 2.
By combining the primary strategy with crossover, the
overall likelihood of being diagnosed with a strategy of
monitoring was 43% (22 of 51) compared with 20% (7 of
35) with conventional testing (p  0.026). Combining the
primary strategy with crossovers allowed the overall diag-
nostic yield for each strategy and the cost of each approach
to be calculated (Fig. 2). The overall diagnostic yield was
comparable between strategies (50% with primary monitor-
ing vs. 47% with primary conventional testing), but the cost
of testing was reduced from $3,683  $1,490 in the
conventional group to $2,937  $579 in the monitored
group (p  0.013). Furthermore, the cost per diagnosis was
reduced from $7,891 $3,193 in the conventional group to
$5,875  $1,159 in the monitored group (p  0.002). This
resulted in a negative ICER ($22,380), implying actual
cost savings with the strategy of monitoring.
The cost per diagnosis for individual tests was calculated.
Tilt testing was most cost effective at $2,901 per diagnosis,
followed by the implantable loop recorder at $6,158 per
diagnosis. External loop recorders ($10,061/diagnosis) and
EP testing ($10,700/diagnosis) were associated with much
greater average costs.
DISCUSSION
We have shown that a primary monitoring approach to
patients with unexplained syncope undergoing cardiovascu-
lar testing is both diagnostically efficient and cost effective.
Despite the relatively high cost and minimally invasive
nature of an implantable loop recorder, primary monitoring
provided a diagnostic approach that yielded more diagnoses
than conventional testing, with favorable cost-effectiveness.
The initial cost of monitoring was greater than that of
conventional testing but was justified in light of its greater
yield. Performance of conventional tests leads to a high
incidence of crossover to the monitored approach, thereby
increasing cost.
This finding does not negate the role of conventional
testing in selected patients when the yield is likely to be
greater than that seen in the current study. Patients capable
of using an external loop recorder should undergo a trial
with this device before an implanted device is inserted,
because of its non-invasive nature. Similarly, tilt-table
testing may have a role in select individuals when neurocar-
diogenic syncope is suspected. This is borne out by the cost
per diagnosis of individual tests, supporting the role for tilt
Figure 1. Outcome in 60 patients randomized to a primary diagnostic strategy of prolonged cardiac monitoring compared with conventional testing with
an external loop recorder and tilt and electrophysiologic testing for investigation of syncope. Although the cost of monitoring was greater than that of
conventional testing, the cost/diagnosis was reduced because of the greater diagnostic yield (p  0.0001).
498 Krahn et al. JACC Vol. 42, No. 3, 2003
Cost of Testing in Syncope August 6, 2003:495–501
testing even if the yield is relatively low. We excluded
patients with a clinical presentation suggesting a high
probability of neurocardiogenic syncope, because we felt it
was not appropriate to consider invasive testing in the
context of a strong clinical diagnosis. This is reflected in the
age of the patients in the current study. The results of the
current study cannot be generalized to other populations
with syncope. This is particularly true in patients with poor
ventricular function who were excluded. Electrophysiologic
testing plays a much greater role in these patients because of
concern of life-threatening ventricular arrhythmias, the
potential risk of sudden death during recurrent symptoms,
and the greater yield of EP testing in this population
(25–30).
The main driver of cost in the conventional arm was EP
testing, which has a diminishing role in patients with
syncope (22). Although it retains a role in patients with
structural heart disease, emerging evidence suggests there is
an unacceptable recurrence and sudden death rate after
negative EP testing in patients with syncope in both
ischemic and non-ischemic cardiomyopathy (25–30). The
current study and several others have demonstrated that EP
testing has a low yield in patients with preserved LV
function and should be considered only for selected patients
when an inducible abnormality is likely or when it is
clinically unacceptable to wait for a recurrent event. In the
latter population, prolonged monitoring appears to be the
approach of choice after non-invasive testing. Clearly, the
order of testing influences both the diagnostic yield and
cost-effectiveness, as demonstrated by the high cost per
diagnosis of EP testing in the current study.
The cost of the strategy of prolonged monitoring was
predominantly influenced by the cost of the implantable
monitor. The cost estimate in this relatively small patient
population reflected the cost of device implantation, follow-
up, and removal, but it did not take into account the
infrequent complication of infection seen with all implanted
devices. Prophylactic antibiotics were administered to all
patients, in keeping with our practice in pacemaker im-
plants. Rare complications such as device migration, ero-
sion, and intolerable pain were not experienced. These
events are so infrequent that they would be unlikely to
influence the overall estimate of the cost of monitoring.
The cost of investigations before being enrolled in the
study reflected the common clinical practice of performing
low-yield cardiovascular and neurologic testing before being
referred to a cardiologist or electrophysiologist. Neurologic
testing was performed in 60% of patients. The costs in the
current study were similar to those seen in our previous
study that evaluated costs in referred patients (31,32) and
considerably less than those reported by Calkins et al. (33).
Study limitations. The current trial enrolled patients with
recurrent, unexplained syncope that warranted referral to a
cardiologist. The results may not be applicable to other
patient groups with syncope, particularly patients who
present with an initial event that may benefit from non-
Figure 2. Cost and diagnostic yield of the two treatment strategies. The results of the testing strategy are shown for all patients in the trial, including those
who crossed over. The overall diagnostic yield of the two strategies was comparable, but the cost per diagnosis of the strategy of primary monitoring was
significantly reduced by $2,016 (p  0.002).
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invasive conventional monitoring. Crossover in the current
study was offered but not mandated, because we thought
that patients may not be willing to pursue a diagnosis any
further after having negative test results in the primary arm.
This was the case in very few of the patients for whom the
conventional approach failed, but in the majority of those
who underwent a year of negative monitoring. This reflects
a practical approach that is in keeping with usual clinical
practice. Efficacy and cost analysis convincingly demon-
strated the benefit of monitoring in the primary strategy,
with consistent findings in those who crossed over.
Electrophysiologic testing is often withheld in patients
with syncope and normal LV function. We chose to include
EP testing because it has been upheld as the test of last
resort in patients with refractory symptoms and no diagnosis
(5,14,22,23). Excluding this would have reduced the sensi-
tivity of the diagnostic protocol and would have withheld
this form of testing from the 38% of study patients who had
some form of structural heart disease without a marked
reduction in LV function.
Finally, the costs are calculated in Canadian dollars,
reflecting Ontario-based fee codes. Although the cost of
health care varies between systems in other countries, the
relative cost of the two strategies is likely to be similar. The
relative cost of invasive, non-invasive, and out-patient
testing between health care systems may have a minor
influence on the costs of the two strategies.
Conclusions. A strategy of prolonged monitoring is a more
cost effective and efficient diagnostic approach than conven-
tional testing in patients with recurrent, unexplained syn-
cope with preserved LV function. The strategy of primary
monitoring significantly reduced cost by $2,016 (p 
0.002).
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